Circulating miR-135 May Serve as a Novel Co-biomarker of HbA1c in Type 2 Diabetes
- PDF / 311,368 Bytes
- 8 Pages / 439.37 x 666.142 pts Page_size
- 11 Downloads / 179 Views
Circulating miR-135 May Serve as a Novel Co-biomarker of HbA1c in Type 2 Diabetes Yousef Khazaei Monfared 1 & Maryam Honardoost 2 Seyed Amir Farzam 4
3
& Mohamad Reza Sarookhani &
Received: 31 July 2019 / Accepted: 23 October 2019/ # Springer Science+Business Media, LLC, part of Springer Nature 2019
Abstract
Hemoglobin A1c (HbA1c) is a reliable marker of insulin resistance in normal glucose tolerance patients; however, several physiological, environmental, and genetic factors may affect HbA1c and cause false results. Therefore, it is essential to use new biomarkers due to increasing diabetes predictive value. Recently, it has been indicated that microRNAs (miRNAs) are involved in the pathophysiology of diabetes, particularly, in insulin resistance pathways. Therefore, miRNAs have the potential to be introduced as new glycemic control biomarkers. The aim of this study was to investigate the association between plasma level of miRNA-135a and HbA1c in patients with prediabetes and type 2 diabetes. In this case-control study, 120 samples were enrolled (healthy individuals, people with type 2 diabetes, and prediabetes) and HbA1c and miR-135a expression level in their plasma samples were evaluated. Multinomial logistic regression and ROC curve analysis were conducted to assess the diagnostic accuracy of plasma miR-135a in T2D , prediabetes, and healthy control groups. Data analysis indicated that miR-135a was significantly elevated in both diabetes/prediabetes samples. Then, subjects were reclassified based on the calculated cutoff value of miRNA. Logistic Regression analysis showed that an increased level of miRNA positively correlated with HbA1c level in prediabetes (Adjusted OR = 1.14, p value = 0.033) and diabetic status (Adjusted OR = 1.27, p value = 0.024 ). miR-135 may provide an assistant marker for HbA1c to detect type 2 diabetes. Keywords miR-135 . HbA1c level . Type 2 diabetes
* Maryam Honardoost [email protected]; [email protected]; http://www.iums.ac.ir/link/iem Mohamad Reza Sarookhani [email protected] Seyed Amir Farzam [email protected] Extended author information available on the last page of the article
Applied Biochemistry and Biotechnology
Introduction Type 2 diabetes (T2D) is diagnosed generally based on the fasting plasma glucose values, oral glucose tolerance test, and measurement of glycated hemoglobin (HbA1c) concentration as per the WHO guidelines [1]. HbA1c is a form of hemoglobin that is measured to evaluate the average three-month blood glucose concentration. HbA1c testing is recommended for blood glucose monitoring in both patients with prediabetes and diabetes. Nonetheless, fasting blood sugar tests are essential in making medical decisions for diabetic patients [2]. In T2D, a high level of HbA1c, indicating poor control of blood glucose levels, has been associated with diabetic complications such as nephropathy, neuropathy, and retinopathy. Furthermore, HbA1c, in combination with serum lipid level help to predict T2D with a possibility of about 0.65–0.75 [3]. Clinic
Data Loading...
